Product
Trikafta
Aliases
elexacaftor, ivacaftor, tezacaftor
Name
Kalydeco
INN Name
Elexacaftor, Tezacaftor, and Ivacaftor
FDA Approved
Yes
5 clinical trials
1 organization
4 indications
2 documents
Indication
Cystic FibrosisIndication
Lung DiseasesIndication
Drug-drug interactionsIndication
Non-cystic Fibrosis BronchiectasisClinical trial
iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations or N1303K CFTRStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Long-term Effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Exertional Symptoms, Exercise Performance, Ventilatory Responses, and Body Composition in Adults With Cystic FibrosisStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon MutationsStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/IvacaftorStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Evaluating Trikafta for the Treatment of Patients With Non-cystic Fibrosis Bronchiectasis (NCFBE)Status: Recruiting, Estimated PCD: 2024-06-01
Document
DailyMed Label: KalydecoOrganization
Vertex Pharmaceuticals IncorporatedDocument
DailyMed Label: Trikafta